相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis
Won-Mook Choi et al.
JOURNAL OF HEPATOLOGY (2023)
The scientific basis of combination therapy for chronic hepatitis B functional cure
Seng Gee Lim et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)
Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B
Daniel Q. Huang et al.
DIGESTIVE DISEASES (2023)
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial
Fan Yang et al.
HEPATOLOGY INTERNATIONAL (2023)
A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naive patients with chronic hepatitis B
Man-Fung Yuen et al.
LIVER INTERNATIONAL (2023)
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B
Lung-Yi Mak et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2023)
Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)
Milan J. Sonneveld et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty
Teresa Broquetas et al.
DIGESTIVE AND LIVER DISEASE (2022)
Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study
Lung-Yi Mak et al.
HEPATOLOGY INTERNATIONAL (2022)
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels
Milan J. Sonneveld et al.
JOURNAL OF HEPATOLOGY (2022)
Current Trend in Antiviral Therapy for Chronic Hepatitis B
Rong-Nan Chien et al.
VIRUSES-BASEL (2022)
Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT
Seng Gee Lim et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui et al.
CLINICAL AND MOLECULAR HEPATOLOGY (2022)
Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis
Young-Suk Lim et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
Grace L. H. Wong et al.
JOURNAL OF HEPATOLOGY (2022)
A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'
Kosh Agarwal et al.
JOURNAL OF HEPATOLOGY (2022)
Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives
Valerio Taverniti et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Man-Fung Yuen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
Man-Fung Yuen et al.
JOURNAL OF HEPATOLOGY (2022)
Novel therapeutic strategies for chronic hepatitis B
Sandra Phillips et al.
VIRULENCE (2022)
Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019
Brittney S. Sheena et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Should Treatment Indications for Chronic Hepatitis B Be Expanded?
Wen-Juei Jeng et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B
Maria Pfefferkorn et al.
JOURNAL OF HEPATOLOGY (2021)
Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B
Do Seon Song et al.
CLINICAL INFECTIOUS DISEASES (2021)
Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients
Mireia Garcia-Lopez et al.
JOURNAL OF HEPATOLOGY (2021)
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial
Fanping Meng et al.
HEPATOLOGY INTERNATIONAL (2021)
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B
Edward J. Gane et al.
HEPATOLOGY (2021)
First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
Lung-Yi Mak et al.
BMC GASTROENTEROLOGY (2021)
The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy
Thomas Berg et al.
JOURNAL OF HEPATOLOGY (2021)
Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation
Takako Inoue et al.
JOURNAL OF HEPATOLOGY (2021)
Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B
Yao-Chun Hsu et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection
Akira Nishio et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance
Jonggi Choi et al.
HEPATOLOGY (2021)
HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy
Lung-Yi Mak et al.
HEPATOLOGY (2021)
Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
Grishma Hirode et al.
GASTROENTEROLOGY (2021)
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B
Florian van Boemmel et al.
HEPATOLOGY COMMUNICATIONS (2021)
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)
Seng Gee Lim et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China
Terry Cheuk-Fung Yip et al.
GASTROENTEROLOGY (2020)
Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
Sung Won Lee et al.
GUT (2020)
Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy
Ivana Carey et al.
HEPATOLOGY (2020)
Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy
Chien-Hung Chen et al.
HEPATOLOGY INTERNATIONAL (2020)
The HBeAg-Negative Gray Zone Phase: A Frequent Condition With Different Outcomes in Western and Asian Patients?
Martin Bonacci et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-titer HBV Carrier Mice
Thomas Michler et al.
GASTROENTEROLOGY (2020)
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
Michel Bazinet et al.
GASTROENTEROLOGY (2020)
Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics
Rong-Nan Chien et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic HBV Infection: Systematic Review and Meta-analysis
Ryan T. Anderson et al.
Clinical Gastroenterology and Hepatology (2020)
Characterization of the antiviral effects of REP 2139 on the HBV lifecycle in vitro
Richard Boulon et al.
ANTIVIRAL RESEARCH (2020)
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2020)
Advances with RNAi-Based Therapy for Hepatitis B Virus Infection
Fiona van den Berg et al.
VIRUSES-BASEL (2020)
New Approaches to the Treatment of Chronic Hepatitis B
Alexandra Alexopoulou et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients
Teresa Broquetas et al.
WORLD JOURNAL OF HEPATOLOGY (2020)
Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis
Jiaye Liu et al.
HEPATOLOGY INTERNATIONAL (2020)
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Patrick Marcellin et al.
LIVER INTERNATIONAL (2019)
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
Thomas Yau et al.
JOURNAL OF HEPATOLOGY (2019)
Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis
Ken Liu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift
Yun-Fan Liaw
HEPATOLOGY INTERNATIONAL (2019)
Restoring, releasing or replacing adaptive immunity in chronic hepatitis B
Mala K. Maini et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study
Jonggi Choi et al.
JAMA ONCOLOGY (2019)
Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir
Ming-Te Kuo et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection
Hye Won Lee et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review
Jiaye Liu et al.
HEPATOLOGY (2019)
Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study
Xiao-Qin Dong et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients
Barbara Testoni et al.
JOURNAL OF HEPATOLOGY (2019)
Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir
Yuanyuan Kong et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide
Tse-Ling Fong et al.
JOURNAL OF VIRAL HEPATITIS (2019)
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection
Sara Ferrando-Martinez et al.
JHEP REPORTS (2019)
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B
Gi-Ae Kim et al.
GUT (2018)
Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers
Maria Pfefferkorn et al.
GUT (2018)
Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone
M. Bonacci et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Systematic review with meta-analysis: Change in liver stiffness during anti-viral therapy in patients with hepatitis B
Antonio Facciorusso et al.
DIGESTIVE AND LIVER DISEASE (2018)
Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections
Keye Du et al.
EXPERT OPINION ON DRUG DISCOVERY (2018)
HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients
Yun-Fan Liaw et al.
GASTROENTEROLOGY (2018)
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues
Carolina Boni et al.
GASTROENTEROLOGY (2018)
Hepatitis B Virus Serum DNA and RNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection
Emily K. Butler et al.
HEPATOLOGY (2018)
Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B
Wen-Juei Jeng et al.
HEPATOLOGY (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation
Laura Rivino et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
Harry L. A. Janssen et al.
JOURNAL OF HEPATOLOGY (2018)
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
Franziska Rinker et al.
JOURNAL OF HEPATOLOGY (2018)
Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients
Kai-Henrik Peiffer et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
X. -J. Kuang et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Hepatitis B virus infection
Man-Fung Yuen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients
C. -H. Chen et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis
Ying Han et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B
Fanny Lebosse et al.
JOURNAL OF HEPATOLOGY (2017)
Serum HBV pgRNA as a clinical marker for cccDNA activity
Katja Giersch et al.
JOURNAL OF HEPATOLOGY (2017)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
Thomas Berg et al.
JOURNAL OF HEPATOLOGY (2017)
Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study
Young Chang et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance
Filippo Oliveri et al.
LIVER INTERNATIONAL (2017)
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs)
Glenda Grossi et al.
LIVER INTERNATIONAL (2017)
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
Christine I. Wooddell et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application
Jianming Hu et al.
VIRUSES-BASEL (2017)
Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels
Yuk-Fai Lam et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2017)
Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues
Teresa Broquetas et al.
PLOS ONE (2017)
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
Marc Bourliere et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Entecavir safety and effectiveness in a national cohort of treatment-naive chronic hepatitis B patients in the US - the ENUMERATE study
J. Ahn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S. K. Sarin et al.
HEPATOLOGY INTERNATIONAL (2016)
Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients
Jose L. Casado et al.
AIDS (2016)
Combination of Tenofovir Disoproxil Fumarate and Peginterferon alpha-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B
Patrick Marcellin et al.
GASTROENTEROLOGY (2016)
Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
George Papatheodoridis et al.
HEPATOLOGY (2016)
Hepatitis B virus receptors and molecular drug targets
Eloi R. Verrier et al.
HEPATOLOGY INTERNATIONAL (2016)
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B
Anna S. Lok et al.
JOURNAL OF HEPATOLOGY (2016)
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study
Pavel Bogomolov et al.
JOURNAL OF HEPATOLOGY (2016)
Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound
Jie Wang et al.
JOURNAL OF HEPATOLOGY (2016)
Mechanisms of HBV-induced hepatocellular carcinoma
Massimo Levrero et al.
JOURNAL OF HEPATOLOGY (2016)
Overview of hepatitis B viral replication and genetic variability
Shuping Tong et al.
JOURNAL OF HEPATOLOGY (2016)
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2016)
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B
Christoph Hoener zu Siederdissen et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su et al.
LIVER INTERNATIONAL (2016)
Viral evasion of intracellular DNA and RNA sensing
Ying Kai Chan et al.
NATURE REVIEWS MICROBIOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Henry L. Y. Chan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
Fabien Zoulim et al.
JOURNAL OF HEPATOLOGY (2015)
Molecular biology of hepatitis B virus infection
Christoph Seeger et al.
VIROLOGY (2015)
Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections
Che C. Colpitts et al.
ACS INFECTIOUS DISEASES (2015)
Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
Wai-Kay Seto et al.
GUT (2015)
Serum Hepatitis B Virus RNA Levels as an Early Predictor of Hepatitis B Envelope Antigen Seroconversion During Treatment With Polymerase Inhibitors
Florian van Boemmel et al.
HEPATOLOGY (2015)
Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon
Lucio Boglione et al.
ANTIVIRAL RESEARCH (2014)
The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment
Chien-Hung Chen et al.
JOURNAL OF HEPATOLOGY (2014)
Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA
Julie Lucifora et al.
SCIENCE (2014)
Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons From Experimental and Clinical Studies
Fabien Zoulim et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency
Danny Ka-Ho Wong et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
BASIC AND TRANSLATIONAL-LIVER
Robert E. Lanford et al.
GASTROENTEROLOGY (2013)
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B
Pietro Lampertico et al.
HEPATOLOGY (2013)
Entecavir Treatment Reduces Hepatic Events and Deaths in Chronic Hepatitis B Patients With Liver Cirrhosis
Grace Lai-Hung Wong et al.
HEPATOLOGY (2013)
Reduction of Hepatitis B Surface Antigen Levels and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients Receiving 10 Years of Nucleoside Analogue Therapy
Wai-Kay Seto et al.
HEPATOLOGY (2013)
Response-Guided Peginterferon Therapy in Hepatitis B e Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
Milan J. Sonneveld et al.
HEPATOLOGY (2013)
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
Patrick Marcellin et al.
HEPATOLOGY INTERNATIONAL (2013)
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely
Stephane Chevaliez et al.
JOURNAL OF HEPATOLOGY (2013)
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin et al.
LANCET (2013)
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D
Lucio Boglione et al.
LIVER INTERNATIONAL (2013)
Medical Virology of Hepatitis B: how it began and where we are now
Wolfram H. Gerlich
VIROLOGY JOURNAL (2013)
Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir
Stephanos J. Hadziyannis et al.
GASTROENTEROLOGY (2012)
Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues
Carolina Boni et al.
GASTROENTEROLOGY (2012)
Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs
Joerg Petersen et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B
Ting-Tsung Chang et al.
HEPATOLOGY (2010)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2008)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection
F van Bömmel et al.
HEPATOLOGY (2004)
Nuclear import of hepatitis B virus capsids and release of the viral genome
B Rabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B
EK Manesis et al.
GASTROENTEROLOGY (2001)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)